NYSEMaterialsMedical Instruments & SuppliesSnapshot 2026-07-23
Reading ATR? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment represents a durable compounder with a focus on maintaining revenue growth and dividend payouts. The current thesis state is stable, supported by recent financial performance that is above the industry average.
The market appears to price in a neutral valuation, with a premium compared to peers. There is an expectations gap, indicating that investors may not fully believe in the company's ability to sustain its recent performance.
Management is focused on increasing revenue growth, particularly in the Pharma and Beauty segments, which has shown positive results. However, operating income has seen limited progress, and there is a moderate risk of missing future earnings estimates.
The long-term thesis hinges on several factors, including the potential for inflation to reaccelerate and the performance of sector bellwethers. Additionally, any cuts to guidance in upcoming calls could negatively impact sentiment.
Overall, ATR's fundamentals are stable, but there are risks that could affect performance in the near term. Not investment advice.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports this improvement, indicating that recent financial performance remains strong. There are no current threats affecting the thesis.
as of 2026-07-23
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Why it matters: This guidance shows how well Aptar is managing costs and growing revenue. Hitting this range would signal strong performance in the Pharma and Beauty segments.
Confirms:Q2 adjusted earnings per share reported within the range of $1.32 to $1.40.
Disproves:Q2 adjusted earnings per share falls below $1.32.
Why it matters: This guidance shows how well Aptar expects to perform in the next quarter. Strong earnings could signal growth in key segments.
Confirms:Aptar reports adjusted earnings per share within the guided range of $1.32 to $1.40.
Disproves:Earnings per share are below $1.32. This shows weaker performance.
Why it matters: Growth in Beauty shows strong demand from consumers and a good market position.
Confirms:Beauty segment sales growth remains above 10% in Q2 2026.
Disproves:Beauty segment sales growth is below 5%. This signals possible market weakness.
Why it matters: Supply chain problems may hurt revenue and margins. Watching this helps check stability.
Confirms one read:Q2 results show minimal impact from supply chain issues.
Confirms the other:Q2 results show a big negative effect from supply chain problems.
Why it matters: The new CEO's plans could reshape Aptar's direction and impact growth. Early signals are important.
Confirms:Aptar shares new plans from the new CEO that match growth goals.
Disproves:No clear initiatives or direction are announced by the new CEO.
Why it matters: Supply chain issues could affect production and sales. Monitoring this helps gauge operational risks.
Confirms one read:Aptar reports no big supply chain problems in Q2.
Confirms the other:Aptar says there are major supply chain problems affecting Q2 results.
Why it matters: Better margins mean improved cost management and product mix. This helps overall profits.
Confirms:The adjusted EBITDA margin went above 19.2% in Q2.
Disproves:Adjusted EBITDA margin falls below 19.2% in Q2.
Why it matters: More share repurchases show confidence in the company. This can help share prices.
Confirms:Aptar plans to repurchase over $100 million in shares next quarter.
Disproves:No major share repurchase activity happens in the next quarter.
Why it matters: New share buyback plans show management's trust in the company's value and future.
Confirms:Announcement of share repurchases worth at least $200 million.
Disproves:No announcement or a reduction in share repurchase plans.
Why it matters: Growth in Pharma helps offset the effects of destocking and boosts overall revenue.
Confirms:Pharma segment reports sales growth of at least 5% in Q2.
Disproves:Pharma segment shows flat or declining sales in Q2.
